Occurrence of Platelet–Monocyte Aggregates in Patients with Metabolic Disorders and Effect of Direct Anticoagulants

Abstract

Background

Platelet–monocyte aggregates (PMA) are modern biomarkers for the early onset of cardiovascular diseases (CVD). PMA occur in the presence of activated platelets (AP), whose incidence is higher in patients with metabolic diseases. These patients frequently benefit from anticoagulant therapy, particularly in advanced disease stages. However, the impact of these drugs on PMA occurrence is unknown.

Materials and Methods

Blood samples from healthy volunteers, patients with type 1 diabetes mellitus (DMT1), type 2 diabetes mellitus (DMT2), dyslipidemia (hypercholesterolemia), and severe forms of familial hypercholesterolemia (FH) were analyzed by flow cytometry to detect both AP and PMA. Subsequently, blood samples were treated with four direct anticoagulants (rivaroxaban, apixaban, dabigatran, or argatroban, all at a final concentration of 1 µM), and PMA were again detected. Anthropological and biochemical parameters were recorded and correlated with AP and PMA.

Results

AP levels were higher solely in DMT2 patients, but PMA occurrence was significantly increased in all patient groups in comparison to that of generally healthy donors, except for FH patients. No sex-related differences were observed, but an increasing trend in AP and PMA incidence was observed with increasing age and BMI. Significant correlations of AP and PMA with anthropological and biochemical parameters were found solely in some groups of patients or in some anticoagulant-treated samples. Only argatroban and apixaban-treated samples significantly decreased PMA occurrence, and this was observed solely in the dyslipidemia patient group.

Conclusion

These findings suggest a potential positive outcome of anticoagulant treatment for metabolic disease patients and confirm PMA as a sensitive marker in patients with metabolic diseases.

Keywords

platelet–monocyte aggregates - metabolic disorders - activated platelets - anticoagulants

• References

• 1 World Health Organization. Cardiovascular diseases (CVDs). World Health Organization. Accessed September 8, 2025 at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
• 2 Margraf A, Zarbock A. Platelets in inflammation and resolution. J Immunol 2019; 203 (09) 2357-2367
• 3 Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019; 129 (01) 12-23
• 4 Etulain J. Platelets in wound healing and regenerative medicine. Platelets 2018; 29 (06) 556-568
• 5 Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11 (04) 264-274
• 6 Rolling CC, Barrett TJ, Berger JS. Platelet-monocyte aggregates: molecular mediators of thromboinflammation. Front Cardiovasc Med 2023; 10: 960398
• 7 Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104 (13) 1533-1537
• 8 Seizer P, Gawaz M, May AE. Platelet-monocyte interactions—a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem 2008; 15 (20) 1976-1980
• 9 Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab 2001; 12 (05) 225-230
• 10 Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2 (01) 16-23
• 11 de Ferranti SD, de Boer IH, Fonseca V. et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation 2014; 130 (13) 1110-1130
• 12 Toft-Nielsen F, Emanuelsson F, Benn M. Familial hypercholesterolemia prevalence among ethnicities—systematic review and meta-analysis. Front Genet 2022; 13: 840797
• 13 Ravnskov U, de Lorgeril M, Kendrick M, Diamond DM. Importance of coagulation factors as critical components of premature cardiovascular disease in familial hypercholesterolemia. Int J Mol Sci 2022; 23 (16) 9146
• 14 Schneider DJ, Tracy PB, Mann KG, Sobel BE. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997; 96 (09) 2877-2883
• 15 Konečný L, Hrubša M, Karlíčková J. et al. The effect of 4-methylcatechol on platelets in familial hypercholesterolemic patients treated with lipid apheresis and/or proprotein convertase subtilisin kexin 9 monoclonal antibodies. Nutrients 2023; 15 (08) 1842
• 16 Mach F, Baigent C, Catapano AL. et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (01) 111-188
• 17 American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes-2025. Diabetes Care 2025; 48 (1, Suppl 1): S1-S5
• 18 Carazo A, Hrubša M, Konečný L. et al. Sex-related differences in platelet aggregation: a literature review supplemented with local data from a group of generally healthy individuals. Semin Thromb Hemost 2023; 49 (05) 488-506
• 19 Ahn KC, Jun AJ, Pawar P. et al. Preferential binding of platelets to monocytes over neutrophils under flow. Biochem Biophys Res Commun 2005; 329 (01) 345-355
• 20 Allen N, Barrett TJ, Guo Y. et al. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. Atherosclerosis 2019; 282: 11-18
• 21 Kossmann H, Rischpler C, Hanus F. et al. Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. Int J Cardiol 2019; 287: 7-12
• 22 Maugeri N, Evangelista V, Celardo A. et al. Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost 1994; 72 (03) 450-456
• 23 Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21 (02) 152-160
• 24 Malle E, Sattler W. Platelets and the lipoproteins: native, modified and platelet modified lipoproteins. Platelets 1994; 5 (02) 70-83
• 25 Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?. World J Diabetes 2014; 5 (04) 444-470
• 26 Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res 2016; 118 (11) 1771-1785
• 27 Periasamy M, Lieb DC, Butcher MJ. et al. Bariatric surgery decreases monocyte-platelet aggregates in blood: a pilot study. Obes Surg 2014; 24 (08) 1410-1414
• 28 Di Minno G, Cerbone AM, Cirillo F. et al. Hemostatic variables in homozygous familial hypercholesterolemia. Effect of regular plasma cholesterol removal by low density lipoprotein apheresis. Arteriosclerosis 1990; 10 (06) 1119-1126
• 29 Puccetti L, Pasqui AL, Pastorelli M. et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90 (03) 476-482
• 30 Barrachina MN, Hermida-Nogueira L, Moran LA. et al. Phosphoproteomic analysis of platelets in severe obesity uncovers platelet reactivity and signaling pathways alterations. Arterioscler Thromb Vasc Biol 2021; 41 (01) 478-490
• 31 Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006; 133 (03) 315-322
• 32 Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7 (03) 223-227
• 33 Paclíková M, Konečný L, Carazo A. et al. Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls. Cardiovasc Diabetol 2025; 24 (01) 323
• 34 Ferreira IA, Mocking AI, Feijge MA. et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26 (02) 417-422
• 35 Sener A, Ozsavci D, Oba R, Demirel GY, Uras F, Yardimci KT. Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?. Clin Biochem 2005; 38 (12) 1081-1087
• 36 Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 2006; 17 (08) 577-585
• 37 Théorêt JF, Yacoub D, Hachem A, Gillis MA, Merhi Y. P-selectin ligation induces platelet activation and enhances microaggregate and thrombus formation. Thromb Res 2011; 128 (03) 243-250
• 38 Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011; 1243: 88-102
• 39 Elalamy I, Chakroun T, Gerotziafas GT. et al. Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients. Thromb Res 2008; 121 (06) 843-848
• 40 Shoji T, Koyama H, Fukumoto S. et al. Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabetic patients. J Atheroscler Thromb 2005; 12 (06) 344-352
• 41 Harding SA, Sommerfield AJ, Sarma J. et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004; 176 (02) 321-325
• 42 Shlomai G, Haran-Appel T, Sella T. et al. High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study. Cardiovasc Diabetol 2015; 14: 80
• 43 Na SP, Ning ML, Ma JF. et al. Association of elevated circulating monocyte-platelet aggregates with hypercoagulability in patients with nephrotic syndrome. Thromb J 2024; 22 (01) 56
• 44 Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella CAM. The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function. Int J Mol Sci 2023; 24 (14) 11739
• 45 Ferroni P, Basili S, Santilli F, Davì G. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol Haemost Thromb 2006; 35 (3-4): 346-354
• 46 Rolling CC, Sowa MA, Wang TT. et al. P2Y12 inhibition suppresses proinflammatory platelet-monocyte interactions. Thromb Haemost 2023; 123 (02) 231-244
• 47 Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73 (03) 232-241
• 48 Ji WJ, Lu RY, Liu JX. et al. The influence of different anticoagulants and time-delayed sample processing and measurements on human monocyte subset and monocyte-platelet aggregate analyses. Cytometry B Clin Cytom 2017; 92 (05) 371-379
• 49 Dunois C. Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines 2021; 9 (05) 445
• 50 Keyl C, Zimmer E, Bek MJ, Wiessner M, Trenk D. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia. Thromb Haemost 2016; 115 (06) 1081-1089